SCHEMBL20239241

SCHEMBL20239241

CCc1cnc(NCc2cc(Oc3ccc(CCNC(C)=O)cc3)nc(C)n2)nc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACACB O00763 9/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 3/20 0.39
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
DGAT2 Q96PD7 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
LMNA P02545 2/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
PTGS1 P23219 1/20 0.37
BLM P54132 1/20 0.37
HIF1A Q16665 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GLA P06280 1/20 0.37
F13A1 P00488 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239192 0.93 OPRM1 (0.40) ACACBSMN1; SMN2ALDH1A1DGAT2OPRM1
SCHEMBL20259192 0.91 DGAT2 (0.47) ACACBSMN1; SMN2ALDH1A1MTNR1AMTNR1B
SCHEMBL20239151 0.90 SMN1; SMN2 (0.45) ACACBSMN1; SMN2ALDH1A1MTNR1AMTNR1B
SCHEMBL20259256 0.88 IGF1R (0.37) SMN1; SMN2DGAT2OPRM1OPRD1OPRK1
SCHEMBL20239167 0.87 SMN1; SMN2 (0.49) ACACBSMN1; SMN2ALDH1A1MTNR1AMTNR1B
SCHEMBL20239175 0.85 DGAT2 (0.42) SMN1; SMN2ALDH1A1DGAT2OPRM1OPRD1
SCHEMBL20259074 0.84 DGAT2 (0.41) SMN1; SMN2ALDH1A1DGAT2LMNAMAPT
SCHEMBL20239173 0.84 SMN1; SMN2 (0.46) ACACBSMN1; SMN2ALDH1A1DGAT2OPRM1
SCHEMBL20239244 0.84 DGAT2 (0.48) ACACBALDH1A1DGAT2OPRM1OPRD1
SCHEMBL20239232 0.83 DGAT2 (0.46) ACACBSMN1; SMN2DGAT2OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT ACACB 152/4885SMN1; SMN2 4828/4885ALDH1A1 1430/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT ACACB 152/4885SMN1; SMN2 4835/4885ALDH1A1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.